Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)
BackgroundImmune checkpoint inhibitors (ICIs) are widely used in lung cancer treatment; however, immune-related adverse events (irAEs) remain an important safety-related research topic. Currently, there is a lack of comprehensive bibliometric analyses …